Express Pharma

NOVEMBER 21, 2023

It helps to enhance the immune function of cancer patients and prevent the side effects of neutropenia caused by chemotherapy. Ryzneuta is a novel long-acting Granulocyte colonystimulating factor (G-CSF), which can stimulate the proliferation, differentiation, and release of neutrophil precursors.

Chemotherapy 96

Chemotherapy Adverse Reactions Immunity Immunization 96

European Pharmaceutical Review

APRIL 27, 2023

Blinatumomab significantly improved survival, with the rate increasing from 66 percent to 93 percent, compared to individuals just given prior chemotherapy. Monoclonal antibody ( mAb ) blinatumomab binds to leukaemia cells on one side and to immune cells on the other side.

Chemotherapy 99

Chemotherapy Immunity Immunization 99

European Pharmaceutical Review

NOVEMBER 24, 2022

Nivolumab (Opdivo), together with chemotherapy has been recommended in the National Institute for Health and Care Excellence NICE final draft guidance for untreated HER2-negative, advanced or metastatic gastric, gastroesophageal junction (GEJ) or oesophageal adenocarcinoma where tumours express programmed death-1 receptor (PD-L1).

Chemotherapy 97

Chemotherapy Immunity Immunization 97

World Pharma News

APRIL 10, 2023

The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma.

Chemotherapy 83

Chemotherapy Immunity Immunization 83

Express Pharma

OCTOBER 25, 2023

Keytruda is an immunotherapy that works with the immune system to help fight cancer cells. It is different from chemotherapy or radiation therapy. The immune system sends certain types of cells called T-cells throughout your body to detect and fight infections and diseases—including cancer.

Immunity 97

Immunity Immunization Chemotherapy 97

Express Pharma

DECEMBER 6, 2023

Additional durvalumab data include results from the , the combination of immunotherapy and chemotherapy demonstrates clinical benefit and addresses unmet needs in early g astric cancer, where there is the greatest potential for cure.

Immunity 102

Immunity Immunization Chemotherapy 102

European Pharmaceutical Review

OCTOBER 1, 2022

A Phase III trial from Shanghai Henlius Biotech is the first study to suggest that the programmed cell death (PD) 1 receptor immune checkpoint inhibitor Hansizhuang (serplulimab) plus chemotherapy can markedly improve survival for extensive-stage small cell lung cancer (ES-SCLC) patients. A follow-up after 12.3 months).

Chemotherapy 89

Chemotherapy Immunity Immunization Hospitals 89

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunity 84

Immunity Immunization Chemotherapy 84

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Chemotherapy 84

Chemotherapy Immunity Immunization 84

European Pharmaceutical Review

DECEMBER 21, 2022

Having patients in the trial achieve full T-cell immunity is outstanding. Researchers predicted Artemis-SCID patients would need less chemotherapy to prepare their marrow for transfusion when their own cells were being used, so only 25 percent of a full dose of busulfan was administered.

Immunity 103

Immunity Immunization Chemotherapy Vaccines 103

Pharmafile

JANUARY 27, 2023

The antibody treatment was previously used as an additional layer of protection against the virus for those with compromised immune systems, such as those undergoing chemotherapy, or organ-transplant patients. read more

Chemotherapy 52

Chemotherapy Immunity Immunization Communication 52

Pharmacy Times

DECEMBER 19, 2022

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunity 109

Immunity Immunization Chemotherapy Pharmaceutical Companies 109

Pharmaceutical Technology

NOVEMBER 24, 2022

The National Institute for Health and Care Excellence (NICE) in the UK has recommended Bristol Myers Squibb ’s (BMS) nivolumab (Opdivo) plus chemotherapy as an option for patients with advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. The PD-1 protein can switch off the immune system of the body.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

epicur

JULY 12, 2023

Chemo Blister Packs For safer, more convenient treatment Epicur® chemotherapy tablets are manufactured in our FDA Registered Outsourcing Facility following cGMP. Personalized care throughout the treatment process We know side effects of chemotherapy treatment can be difficult for your patients and their owners. Targeted drug therapy.

Chemotherapy 85

Chemotherapy Immunity Immunization Vaccines 85

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

Chemotherapy 52

Chemotherapy Labelling Immunity Immunization 52

European Pharmaceutical Review

SEPTEMBER 25, 2023

The humanised IgG4 anti-PD-1 antibody is indicated for unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy. The treatment is currently under review by the US FDA and the European Medicines Agency (EMA) for advanced or metastatic ESCC after prior chemotherapy.

Chemotherapy 91

Chemotherapy Immunity Immunization 91

Pharmacy Times

JUNE 3, 2023

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

Chemotherapy 29

Chemotherapy Immunity Immunization 29

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunity 105

Immunity Immunization Chemotherapy Hospitals 105

Big Molecule Watch

OCTOBER 31, 2023

The active ingredient in LOQTOZI, toripalimab, is a monoclonal antibody that binds programmed death receptor-1 (PD-1) and blocks its interactions with ligands PD-L1 and PD-L2 with high potency, enabling the immune system to activate and kill the tumor.

Chemotherapy 62

Chemotherapy Immunity Immunization 62

pharmaphorum

JANUARY 3, 2023

Over recent years, there has been a growing consensus that using chemotherapy and aggressive treatments towards the end-of-life should be avoided, where possible, due to the lower quality of life reported. Once no cure can be found for a patient’s condition, decisions must be made about what is the most suitable path forwards.

Chemotherapy 105

Chemotherapy Immunity Immunization Hospitals 105

European Pharmaceutical Review

JANUARY 26, 2023

CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells. Could CAR T therapies be manufactured in one day?

Chemotherapy 120

Chemotherapy Immunity Immunization 120

Pharmaceutical Business Review

MARCH 6, 2024

A monoclonal antibody, Dostarlimab works by aiding the immune system in combating cancer. Administered as a 30-minute intravenous infusion in hospitals, it has shown in clinical trials to enhance life expectancy and prolong the period before the cancer’s progression when given along with platinum-based chemotherapy.

Chemotherapy 64

Chemotherapy Immunity Immunization Hospitals 64

pharmaphorum

NOVEMBER 29, 2022

Tecentriq is a monoclonal antibody designed to bind with PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blockings its interactions with both PD-1 and B7.1 Patients given the Tecentriq plus chemotherapy combination survived a median of 16 months after treatment, compared with 13.4

Chemotherapy 52

Chemotherapy Immunity Immunization 52

pharmaphorum

MAY 30, 2022

“An antibody-drug conjugate is where you connect and link a chemotherapy to an antibody,” Verma said. So there’s a Trojan horse-like mechanism to deliver chemotherapy right to the cancer cell.”. While directed chemotherapy isn’t totally free of side effects, it reduces them.

Chemotherapy 115

Chemotherapy Immunity Immunization 115

European Pharmaceutical Review

DECEMBER 28, 2023

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed.

Immunity 100

Immunity Immunization Chemotherapy Packaging 100

Pharmaceutical Business Review

MARCH 8, 2024

It demonstrated preclinical efficacy in hindering cancer cell growth and proliferation, inducing immune cell infiltration into tumours and preventing fibrosis development. The oral therapy targets highly fibrotic cancer indications that overexpress autotaxin, such as pancreatic, liver, colorectal, ovarian, and breast cancers.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

European Pharmaceutical Review

MAY 12, 2023

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.

Vaccines 92

Vaccines Immunity Immunization Chemotherapy 92

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy Labelling Immunity Immunization 52

pharmaphorum

OCTOBER 22, 2021

The European Commission has given a green light to Opdivo (nivolumab) with chemotherapy for previously-untreated patients with HER2-negative oesophageal, gastric and gastroesophageal junction (GEJ) cancer whose tumours express the PDL-1 biomarker with a score of five or more. months compared to 11.4 months, respectively.

Chemotherapy 103

Chemotherapy Immunity Immunization 103

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical Companies 104

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Immunity 104

pharmaphorum

JANUARY 19, 2022

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone.

Chemotherapy 58

Chemotherapy Immunity Immunization 58

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. Cancer Ther. 2020; 19(10): 2044–56.

Immunity 93

Immunity Immunization Chemotherapy 93

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunity 93

Immunity Immunization Chemotherapy 93

Pharmaceutical Technology

JULY 8, 2022

Xenetic has obtained exclusive intellectual property licence for usage of DNases in oncology including systemic co-administration of DNases along with standard treatments, such as chemotherapy, radiation and checkpoint inhibitors, or in combination with standard chimeric antigen receptor (CAR) T therapies.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

pharmaphorum

SEPTEMBER 6, 2022

The Nijmegen, Netherlands-based biotech was founded in 2018 to develop therapies designed to change the balance of protein expression within the tumour ‘microenvironment’, which can defend cancers against the immune system, and is increasingly becoming a source of new targets in oncology. The Series A round includes €3.6

Chemotherapy 96

Chemotherapy Immunity Immunization 96